SAN DIEGO, November 6, 2017 – ProSciento Inc., metabolism-focused, full scope clinical R&D services provider, will present study results at this week’s European Association for the Study of the Liver (EASL) Nonalcoholic Fatty Liver Disease (NAFLD) Summit.
An abstract of the presentation titled ‘Application of a non-invasive integrated screening approach to facilitate enrollment of clinical trials with investigational NAFLD/NASH therapeutics’ is available at this link.
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
For business development inquires:
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427